Edwards Lifesciences stock holds near upper 52-week range as institutional buying continues

Edwards Lifesciences stock (ISIN US28176E1082) is trading in the upper half of its recent range, with a closing price of 90.78 USD on September 1, 2026, according to market data compiled by MarketBeat.

Stock trades well above 52-week low

Market data from Yahoo Finance show that Edwards Lifesciences shares have a 52-week range between 58.93 USD and 96.12 USD, with a recent prior closing level of 68.02 USD as of October 24, 2024. With the stock now at 90.78 USD as of September 1, 2026, it is trading roughly 31.85 USD above the 52-week low and only 5.34 USD below the 52-week high, placing it clearly in the upper segment of its one-year trading corridor. The same data set indicates a market capitalization of 41.12 billion USD as of the October 2024 snapshot, providing investors with a sense of the company’s scale in the medical technology sector.

The valuation metrics reported in that quote show a trailing price-to-earnings ratio of 26.87 based on trailing twelve-month earnings per share of 2.54 USD as of the October 2024 reference date. This implies that, on those historical fundamentals, the market was willing to pay nearly 27 times earnings for Edwards Lifesciences, a level typical for a premium medical technology name with structural heart and critical care exposure.

Institutional investors and analyst view

According to recent coverage compiled by MarketBeat on September 2, 2026, Edwards Lifesciences continues to attract institutional capital, with multiple asset managers and pension funds disclosing new or increased positions in the shares during August 2026. These filings include purchases by large investment firms and pension plans, underlining that professional investors remain engaged at price levels close to the upper end of the current 52-week band.

The same overview notes that the stock holds an average analyst recommendation described as a moderate buy as of early September 2026. That consensus combines buy and hold ratings and serves as a directional benchmark for many investors. While individual price targets are not detailed in the latest summary, the earlier 1-year target estimate of 75.62 USD cited by Yahoo Finance as of October 24, 2024, now stands well below the current market price of 90.78 USD, indicating that the stock has already moved beyond that historical target range.

Transcatheter heart therapies remain core product area

Edwards Lifesciences is best known for its transcatheter heart valve therapies, including transcatheter aortic valve replacement systems used to treat patients with severe aortic stenosis who are at elevated surgical risk. These products have helped the company build a leading position in structural heart interventions, a market segment highlighted in recent industry research as a key growth driver.

Stock overview and investor perspective

For investors tracking the stock via European venues, Edwards Lifesciences is also represented on the Frankfurt Stock Exchange under the ticker UJ9, where market data tools indicate that quotes were updated around September 2, 2026. While liquidity is typically higher on the company’s primary listing on the New York Stock Exchange under the symbol EW, the Frankfurt listing offers an additional access point for investors in the DACH region.